TO: AC Transit Board of Directors
FROM: Jill A. Sprague, General Counsel
Michael A. Hursh, General Manager
SUBJECT: AC Transit Vaccination Plan
BRIEFING ITEM
RECOMMENDED ACTION(S):
Title
Consider receiving a preliminary report on the development of AC Transit's Vaccination Plan for COVID-19 vaccinations.
Body
STRATEGIC IMPORTANCE:
Goal - Safe and Secure Operations
With the Food and Drug Administration's (FDA) emergency use authorization for two COVID-19 vaccines, and the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices' (ACIP) identification of public transit workers as a high priority group to be included in Phase 1b of vaccine prioritization, it is imperative that the District have a plan for the implementation and administration of vaccines to its employees.
BUDGETARY/FISCAL IMPACT:
The fiscal impact of a Vaccination Plan is currently unknown, but may include costs associated with administering vaccinations, education and communication campaigns, and pay associated with "on the clock" vaccinations.
BACKGROUND/RATIONALE:
After many long months of the COVID-19 pandemic, there are now two COVID-19 vaccines approved by the FDA for emergency use. The vaccines will be a vital tool for controlling and eventually ending this pandemic that has caused so much loss, pain, and disruption. This next essential step in the fight against COVID-19 will take time - but things are moving in the right direction.
Vaccine distribution has been separated into phases, based on ACIP's identification of high-risk, high priority groups, who will receive vaccines first:
* Phase 1a - approximately 24 million people1:
o Health care workers - because of their higher risk for exposure, and to help prevent them from transmitting COVID-19 to patients
o Residents of long-term care facilities - because they represent 40% of COVID-19 deaths
* Phase 1b - approximately 51 million people:
o People age 75 years and older
o Essen...
Click here for full text